<DOC>
	<DOCNO>NCT01645826</DOCNO>
	<brief_summary>The purpose study determine cardizem effective treatment nitric oxide non-responder pulmonary arterial hypertension .</brief_summary>
	<brief_title>Efficacy Study Cardizem Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Adult participant Confirmed WHO class I pulmonary arterial hypertension Nitric Oxide NonResponders right heart catheterization Experience dyspnea , NYHA IIIIV poor oxygenation quality life despite standard treatment Must able swallow medication Pulmonary hypertension secondary 1 ) elevation pulmonary venous pressure ( i.e . left heart disease ) , 2 ) chronic hypoxemic state lung disease COPD , sleepdisordered breathing , alveolar hypoventilation disorder , chronic exposure high altitude developmental abnormality 3 ) chronic thromboembolic disease , 4 ) sarcoidosis , 5 ) Lymphangiomyomatosis , 5 ) Pulmonary Langerhans Cell Histiocytosis Already calcium channel blocker Systolic blood pressure le 90 Heart rate le 55 Pregnant Can sign inform consent Right heart failure Pulmonary Venoocclusive disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>